223786-49-0

Usage

Uses

Used in Medicinal Chemistry:
1-(4-Nitrophenyl)piperidine-4-carboxamide is used as a building block for the synthesis of pharmaceutical compounds, contributing to the development of new medications for a range of diseases.
Used in Pharmaceutical Compound Synthesis:
As a chemical intermediate, 1-(4-Nitrophenyl)piperidine-4-carboxamide is used in the creation of various pharmaceutical compounds, enhancing the diversity and effectiveness of available treatments.
Used in the Preparation of Nitrogen-Containing Heterocycles:
The presence of the nitro group in 1-(4-Nitrophenyl)piperidine-4-carboxamide makes it a useful precursor for the preparation of nitrogen-containing heterocycles, which are important in the field of organic chemistry and pharmaceuticals.
Used in Drug Development:
1-(4-Nitrophenyl)piperidine-4-carboxamide exhibits potential biological activities and is studied for its role in the development of new drugs, aiming to address various diseases and improve patient outcomes.

Upstream product

• 39546-32-2 4-carboxamidopiperidine 
• 350-46-9 4-Fluoronitrobenzene 
• 223786-53-6 1-(4-nitrophenyl)piperidine-4-carboxylic acid 

Downstream Products

• 223786-50-3 1-(4-amino-phenyl)-piperidine-4-carboxylic acid amide 

Relevant academic research and scientific papers

The liquid crystal aligning agent, liquid crystal alignment film, the liquid crystal display element, phase difference film and method of manufacturing the same, polymer and compound

The invention provides a liquid crystal alignment agent, a liquid crystal alignment film, a liquid crystal display element, a phase different film, a method of making a phase difference film, a polymer, and a compound. The invention provides the liquid cr

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity

Factor Xa (fXa) is a serine protease involved in the coagulation cascade, which has received great interest as a potential target for the development of new antithrombotic drugs. Herein we report a novel series of fXa inhibitors in which the 1,4-diazepane moiety was designed to interact with the S4 aryl-binding domain of the fXa active site. Compound 13 (YM-96765) showed potent fXa inhibitory activity (IC50=6.8nM) and effective antithrombotic activity without prolonging bleeding time.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.